Key Points
- DexCom EVP Sadie Stern sold 2,565 shares for approximately $220,975 at an average price of $86.15 under a pre-arranged Rule 10b5-1 plan, reducing her ownership by 2.04%.
- DexCom reported quarterly EPS of $0.70, beating estimates of $0.61, while revenue reached $1.31 billion, up 13.1% year over year.
- Wall Street remains broadly positive, with a consensus “Moderate Buy” rating and an average price target of $89.09; institutional investors own 97.75% of the company.
DexCom, Inc. (NASDAQ:DXCM - Get Free Report) EVP Sadie Stern sold 2,565 shares of DexCom stock in a transaction on Monday, September 28th. The stock was sold at an average price of $86.15, for a total value of $220,974.75. Following the sale, the executive vice president owned 123,478 shares in the company, valued at $10,637,629.70. This trade represents a 2.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Sadie Stern also recently made the following trade(s):
- On Thursday, August 27th, Sadie Stern sold 2,565 shares of DexCom stock. The shares were sold at an average price of $88.37, for a total value of $226,669.05.
DexCom Stock Down 0.4%
Shares of NASDAQ:DXCM opened at $86.29 on Thursday. DexCom, Inc. has a 1 year low of $54.11 and a 1 year high of $92.59. The company has a market capitalization of $32.56 billion, a PE ratio of 34.11, a price-to-earnings-growth ratio of 1.45 and a beta of 1.42. The business has a fifty day moving average price of $86.11 and a two-hundred day moving average price of $74.32. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.73 and a quick ratio of 1.43.
DexCom (NASDAQ:DXCM - Get Free Report) last released its earnings results on Thursday, July 30th. The medical device company reported $0.70 EPS for the quarter, topping analysts' consensus estimates of $0.61 by $0.09. The company had revenue of $1.31 billion for the quarter, compared to analysts' expectations of $1.29 billion. DexCom had a return on equity of 35.94% and a net margin of 20.12%.The business's revenue for the quarter was up 13.1% compared to the same quarter last year. During the same period in the previous year, the business posted $0.48 EPS. Analysts forecast that DexCom, Inc. will post 2.64 earnings per share for the current year.
Wall Street Analysts Forecast Growth
A number of research analysts have weighed in on the stock. Weiss Ratings upgraded shares of DexCom from a "hold (c-)" rating to a "hold (c)" rating in a research note on Tuesday, August 11th. Wells Fargo & Company raised their price target on shares of DexCom from $85.00 to $90.00 and gave the stock an "overweight" rating in a research note on Friday, July 31st. Canaccord Genuity Group set a $90.00 price target on shares of DexCom and gave the stock a "buy" rating in a report on Monday, August 3rd. UBS Group set a $96.00 price objective on DexCom and gave the company a "buy" rating in a research note on Tuesday, July 28th. Finally, Royal Bank Of Canada increased their price objective on DexCom from $85.00 to $90.00 and gave the company an "outperform" rating in a report on Friday, July 31st. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $89.09.
View Our Latest Stock Report on DexCom
Hedge Funds Weigh In On DexCom
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. QRG Capital Management Inc. increased its stake in shares of DexCom by 5.3% in the second quarter. QRG Capital Management Inc. now owns 31,772 shares of the medical device company's stock worth $2,140,000 after purchasing an additional 1,586 shares in the last quarter. Sequoia Financial Advisors LLC raised its position in shares of DexCom by 15.1% in the second quarter. Sequoia Financial Advisors LLC now owns 19,116 shares of the medical device company's stock valued at $1,287,000 after purchasing an additional 2,509 shares during the period. Tidal Investments LLC lifted its stake in shares of DexCom by 6.5% during the 2nd quarter. Tidal Investments LLC now owns 65,922 shares of the medical device company's stock valued at $4,440,000 after buying an additional 3,995 shares in the last quarter. Van Hulzen Asset Management LLC purchased a new stake in shares of DexCom during the 2nd quarter valued at approximately $230,000. Finally, Scholtz & Company LLC boosted its holdings in DexCom by 12.7% in the 2nd quarter. Scholtz & Company LLC now owns 77,334 shares of the medical device company's stock worth $5,208,000 after buying an additional 8,686 shares during the period. Institutional investors own 97.75% of the company's stock.
About DexCom
(
Get Free Report)
DexCom, Inc (NASDAQ: DXCM) develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes. Its technology uses a small wearable sensor to measure glucose levels continuously and transmit readings to a compatible receiver, smartphone or other connected device, helping users monitor glucose trends and make more informed treatment and lifestyle decisions.
The company's product portfolio includes the Dexcom G7 and Dexcom G6 real-time CGM systems, as well as related software and digital health tools such as Dexcom Clarity for glucose data analysis and reporting.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
